Molecular switches under TGFβ signalling during progression from cardiac hypertrophy to heart failure

Area of Science:

• Cardiology
• Molecular Biology
• Pathophysiology

Background:

• Cardiac hypertrophy is a compensatory response to increased workload, such as after myocardial infarction or pressure overload.
• While initially adaptive, sustained cardiac hypertrophy is a major risk factor for heart failure development.
• Pathological cardiac remodeling involves cardiomyocyte dysfunction, apoptosis, necroptosis, and fibrosis, often mediated by shared signaling pathways.

Purpose of the Study:

• To review molecular switches that shift compensated cardiac hypertrophy towards heart failure.
• To highlight the role of transforming growth factor-beta (TGFβ) superfamily signaling in this transition.
• To discuss potential therapeutic targets for mitigating heart failure progression.

Main Methods:

• Literature review of signaling pathways involved in cardiac remodeling.
• Analysis of molecular mechanisms underlying the switch from compensated to decompensated hypertrophy.
• Focus on the TGFβ superfamily's role in pathological cardiac processes.

Main Results:

• Similar signaling pathways mediate hypertrophy, cell death, and fibrosis.
• Subtle alterations in signaling cascades can trigger the transition to heart failure.
• The TGFβ superfamily plays a critical role in pathological cardiac remodeling.

Conclusions:

• Understanding molecular switches is key to preventing heart failure progression.
• Targeting TGFβ superfamily signaling offers potential therapeutic strategies.
• Pharmacological interventions could attenuate the development of heart failure from cardiac hypertrophy.